Oligosaccharide ingredient

FIELD: chemistry.

SUBSTANCE: invention relates to an oligosaccharide ingredient for adding to nutritional compositions or food products, which contains glycosylated amino acids and peptides of general formula RnSacm, where R is an amino acid residue, Sac is a monosaccharide selected from a group comprising N-acetyl-neuraminic acid, N-acetyl-galactosamine and galactose, n has a value between 1 and 10 with the proviso that if n equals 1, R is a threonine residue or a serine residue and if n has a value between 2 and 10, the peptide contains at least one threonine or serine residue, m has a value between 2 and 4 and at least 20 mol % of the ingredient is N-acetyl-neuraminic acid, where the oligosaccharide ingredient contains 15-20 mol % N-acetyl-galactosamine, 15-25 mol % galactose, 20-50 mol % N-acetyl-neuraminic acid and 15-25 mol % threonine or serine or mixture thereof.

EFFECT: obtaining an oligosaccharide ingredient.

7 cl, 1 tbl, 2 ex

 

The technical field to which the invention relates.

The invention relates to an oligosaccharide ingredient enriched in sialic acid to the food products containing the specified oligosaccharide ingredient, and to methods for the specified oligosaccharide ingredient.

The level of technology

It is known that human milk contains a large number of not digested oligosaccharides. In fact, nevereverever oligosaccharides are the third largest solid component (after lactose and lipids) in breast milk, with a concentration of 12-15 g/l in colostrum and 5-8 g/l in Mature milk. Oligosaccharides of human milk is very resistant to enzymatic hydrolysis, which suggests that the main function of these oligosaccharides may occur regardless of their caloric content.

In the last two decades, the chemical structure of the oligosaccharides of human milk were investigated using NMR spectroscopy and mass spectrometry. Each individual oligosaccharide is based on a combination of glucose, galactose, sialic acid (N-acetylneuraminic acid), fucose and/or N-acetylglucosamine with many links between them, leading thus to a huge number of different oligosaccharides in human milk - more than 130 of these structures was the IDA is tapicerowane to the present time. Almost all of them have a molecule of lactose on the restored end, while the end position on the unrecovered end is sialic acid (if present).

Of particular interest is the large number cialisovernight oligosaccharides in human milk. Sialic acid is a sugar with a skeleton from 9 carbon, which is a structural and functional component of gangliosides in the brain. It is believed that it plays a significant role in transmitting nerve cells, in the formation of memory and in the intercellular connections. Studies on rats show that early feeding of sialic acid to increase the content of sialic acids in gangliosides of the brain and improves learning ability in having good nutrition and undernourished animals, and that these changes persist into adulthood.

Breast milk is recommended for all infants. However, in some cases, breast-feeding is not effective or is not favorable for medical reasons, or because the mother chooses not to breastfeed. Baby formula developed for such situations. However, cow's milk is commonly used as the basis of commercially available infant formula, has a much lower content validirovannyj oligosaccharides compared to man the ical milk. As the structure of human milk and the functions of its individual components become better understood, it becomes clear that you may need increased levels of sialic acid in children mixtures based on cow's milk.

There are several sources of sialic acids, including N-acetylneuraminic acid; sialyllactose, and other Valerevna oligosaccharides; gangliosides containing sialic acid; and peptide casinolocated. Chaseonlinebillpay or CGMP is great, enriched with carbohydrates hydrophilic peptide is C-terminal functional group of κ-casein from which it can be carved or enzymatic processing to acid. In the application for U.S. patent No. 2005/0096295 proposed to increase the content of sialic acid in infant formula by including a new CGMP-ingredient with enhanced concentration of sialic acid. This ingredient contains more than 60 mg of sialic acid per gram of peptide compared to 40-60 mg/g of peptide in natural CGMP. It can be obtained either by fractionation using anion chromatography or partial hydrolysis with subsequent fractionation using anion chromatography.

However, there remains a need for other components enriched in sialic acid is th, which can be used for enrichment of infant formula and other nutritional compositions of this important component.

The invention

The present invention provides an oligosaccharide ingredient containing glikozilirovanie amino acids and peptides of General formula RnSacmwhere R is an amino acid residue. Sac is a monosaccharide selected from the group consisting of N-acetylneuraminic acid, N-atsetilgalaktozamin and galactose, n has a value between 1 and 10 with the proviso that if the value of n is 1, R is a residue of threonine or serine, and if n has a value between 2 and 10, the peptide contains at least one residue is threonine or serine, m has a value from 2 to 4 and N-acetylneuraminic acid is at least 20 molar % of an ingredient.

This ingredient is a new enriched in sialic acid food ingredient, which is suitable for adding to nutritional compositions, such as infant formula, to improve the content of sialic acid in the composition.

The invention additionally extends to a method of obtaining oligosaccharide ingredient containing glycosylated amino acids and peptides of General formula RnSacmwhere R is an amino acid residue. Sac is a monosaccharide selected from the group, the content is overall N-acetylneuraminic acid, N-atsetilgalaktozamin and galactose, n has a value between 1 and 10 with the proviso that if the value of n is 1, R is a residue of threonine or serine, and if n has a value between 2 and 10, the peptide contains at least one residue is threonine or serine, m has a value from 2 to 4, and N-acetylneuraminic acid is at least 20 molar % of an ingredient, where the method comprises a stage of hydrolysis of casinolocated ectoprocta and endoproteases to obtain a mixture of free amino acids and peptides with a chain length from 2 to 10 and the stage nanofiltration gidralizovanny mixture for selecting the fraction having a molecular weight from 1000 to 2000 daltons.

The invention also includes a food product containing the above oligosaccharide ingredient. Food is optional, baby food or infant formula, but also the product may be any food or drink consumed by children, infants or adults. Consumption of food containing such oligosaccharide ingredient can improve the incorporation of sialic acids in gangliosides of the brain and thus improve the related function of neurons, such as neurotransmission.

Disclosure of inventions

In the present description the following words are given with definitions that must be taken into account when reading and inter is retali description examples and claims.

"CGMP" - caseinophosphopeptides, i.e. glycomacropeptide, which is cleaved from bovine κ-casein by the action of the enzyme rennin.

"Infant formula" is a food product that is designed for balanced nutrition of infants during the first four to six months of life and for partial power in the next period. The term covers both basic and advanced recipes.

"Sialic acid" - N-acetylneuraminic acid.

The invention provides an oligosaccharide ingredient containing glycosylated amino acids and peptides of General formula RnSacmwhere R is an amino acid residue, Sac is a monosaccharide selected from the group consisting of N-acetylneuraminic acid, N-atsetilgalaktozamin and galactose, n has a value between 1 and 10 with the proviso that if the value of n is 1, R is a residue of threonine or serine, and if n has a value between 2 and 10, the peptide contains at least one residue is threonine or serine, m has a value from 2 to 4 and N-acetylneuraminic acid is at least 20 molar % of an ingredient, and also provides food for children and adults, and containing such oligosaccharide ingredient.

Preferably, if n has a value from 1 to 3, and m has a value of 3 or 4. Ingr diet contains, at least 20 molar % of sialic acid, as part sacharides circuit associated with a hydroxyl group of threonine or serine. Sialic acid can be part of a chain, or may itself be a Deputy monosaccharide units in the chain. Thus, the oligosaccharide ingredient may contain the following monosaccharides:

Connectionmolar %
N-atsetilgalaktozamin (GalNAc)15-25
galactose (Gal)15-25
N-acetylneuraminic acid (NeuAc)50-20

Oligosaccharide ingredient may contain from 15 to 25 molar percent of the mixture of serine and threonine.

Oligosaccharide ingredient may contain the following glycosylated amino acids or peptides: -

NeuAc-α-2,3-Gal-α-1,3-(NeuAc-α-2,6-)-GalNAc-Rn

NeuAc-α-2,3-Gal-α-1,3-GalNAc-Rn

Gal-β-l,3-(CNeuAc-α-2,6-)-GalNAc-Rn

Gal-β-1,3-GalNAc-Rn

Oligosaccharide ingredient according to the invention can be obtained by hydrolysis of CGMP by ectoprocta and endoprotease to obtain a mixture of free amino acids and peptides with a chain length from 2 to 10 and nanofiltration gidralizovanny mixture for sampling fractions, the region is giving a molecular weight of from 1000 to 2000 daltons.

By itself CGMP is a byproduct of cheese making, in which whole milk is processed by the enzyme rendina for precipitation of the casein. In this process CGMP cleaved from κ-casein and remains in solution together with whey protein. This product is known as sweet whey. CGMP may be separated from the whey by any known in this field by the way. A suitable method is described in European Patent No. 986312.

The hydrolysis can be carried out using an appropriate combination of enzymes. One example of a commercially available system of enzymes with Exo - and endoprotease activity is the product with the trademark Flavourzyme®sold unit "Novozymes" company "Novo Nordisk".

The product of hydrolysis is a mixture of free amino acids, glycosylated threonine and serine, glycosylated peptides containing at least one residue is threonine or serine, and deglycosylated peptides, where the peptides have a chain length of 2 to 10 amino acid residues. This mixture undergoes nanofiltration for the separation and selection of the faction, with a range of molecular weights from 1000 to 2000 daltons. This fraction will contain oligosaccharide ingredient of the invention.

In a preferred aspect of the invention described above oligosaccharide ingredient is included in the food product is CT. In the context of the present invention, the term "food product" includes any usable material. Thus, it can be a product intended for human consumption, in particular, children blend the mixture for later meals, baby food, such as baby cereals, etc. In particular, oligosaccharide ingredient according to the invention can be included in baby formula, in the mixture after year, in milk or in a mixture of grains.

The food product may be prepared by any suitable method known in this field, in accordance with the product type and oligosaccharide ingredient according to the invention can be added to the product at an appropriate stage in the production process. For example, infant formula may be prepared by mixing the source of proteins, any of carbohydrates other than lactose, and fat source in appropriate proportions. If necessary, can be added emulsifiers. Vitamins and minerals can be added at this stage, but are usually added later in order to avoid thermal degradation. Any lipophilic vitamins, emulsifiers, etc. may be dissolved in the fat before mixing. Then, for forming the liquid mixture can be added to water, preferably subjected to reverse osmosis.

Thereafter, the liquid mixture may the be heat-treated to reduce bacterial contamination. For example, the liquid mixture may be rapidly heated to a temperature in the range from about 80°to about 110°C for from about 5 seconds to about 5 minutes. The treatment can be carried out by the injection of steam or by using a heat exchanger, for example, using a plate heat exchanger.

Then, the liquid mixture may be cooled to a temperature of from about 60°to about 85°C., for example, using instant cooling. Thereafter, the liquid mixture may be homogenized, for example, in two stages, at a pressure of from about 7 MPa to about 40 MPa in the first stage, and from about 2 MPa to about 14 MPa in the second stage. Next gomogenizirovannogo mixture may be further cooled to add heat-sensitive components, such as vitamins and minerals. At this stage it is convenient to standardize the pH and the content of dry substances in a homogenized mixture.

Gomogenizirovannogo mixture is transferred to a suitable dryer such as a spray dryer or lyophilizator, and converted into powder. The powder should have a moisture content less than about 5 wt.%.

Oligosaccharide ingredient according to the invention can be added directly in the nursery mix dry mix and liquid at the stage of mixing, as discussed above. In both cases, it should be understood that the addition of ingredient involves simultaneous relax is of a certain number of amine nitrogen and therefore, it may be necessary to adjust the protein content in infant formula or in another product, which is added ingredient, at the discretion of the person skilled in the art. Acceptable protein content and amino acid profile of infant formula defined in the legislation, for example in the European Commission Directive 91/321/EEC of 14 may 1991, and the person skilled in the art will be able to simply adjust the protein content and amino acid profile of infant formula, taking into account the additional imposed by ingredient according to the invention the amine nitrogen, and the content of threonine and serine.

The final concentration of oligosaccharide ingredient in a child or infant food or mixture may range from 0.2 to 4.0%, preferably from 0.5 to 2.0 wt.% dry matter. However, these quantities can not be considered as limiting and should be adapted for the target population, for example, based on the weight and the age or health of the child or infant. Preferably, if the mixture or food containing oligosaccharide ingredient of the invention, are given to the child at every meal.

Although the preferred food-additives, specially focused on the nutrition of children and infants can also be a useful food product is s-additive without a specific purpose, or intended for the adult population. For example, oligosaccharide ingredient according to the invention can be included in the medical food and food for the elderly. Such foods can include yogurt, milk, curd, cheese, fermented milk, fermented milk products, ice cream products based on fermented grains, or milk products, among others. Additionally, oligosaccharide ingredient of the invention, a food product, such as infant formula may contain one or more additional oligosaccharides, which are added separately.

Hereinafter the invention will be illustrated by reference to the following example.

Example 1

Below is an example of the composition of infant formula containing oligosaccharide ingredient of the present invention.

linoleic acid (g) 2,2
Nutrient100 kcalPer liter
Energy (kcal)100670
Protein (g)1,8312,3
Fat (g)5,335,7
0,795,3
α-linolenic acid (mg)101675
lactose (g)11,274,7
oligosaccharide ingredient (g)0,151
minerals (g)0,372,5
Na (mg)23150
K (mg)89590
Cl (mg)64430
Ca (mg)62410
P (mg)31210
Mg (mg)750
Mn (µg)850
Se (µg)213
Vitamin A (mcg units of retinol)105700
Vitamin D (µg)1,510
Vitamin E (mg% tocopherol)0,8of 5.4
Vitamin K1 (μg)854
Vitamin C (mg)1067
Vitamin B1 (mg)0,070,47
Vitamin B2 (mg)0,151
Niacin (mg)16,7
Vitamin B6 (mg)0,0750,5
Folic acid (µg)960
Pantothenic acid (mg)0,453
Vitamin B12 (µg)0,32
Biotin (µg)15
Choline (mg)1067
Fe (mg)1,28
I (g)15100
Cu (mg)0,060,4
Zn (mg)0,755

Example 2

50 g of casinolocated ("Biopure GMP", Davisco, USA) was dissolved to 10% (wt./about.) in 500 ml of deionized water. The solution was heated to 40°C for 30 minutes with careful stirring and recirculation through the laboratory system tangential filtration ("Millipore, USA) with one cassette filter "Pellicon 1000 Da" when the inlet pressure of 1.2 bar and without pressure retentate.

Subsequently was added aminopeptidase from Aspergillus oryzae ("Flavourzyme 1000L", containing 1000 units of amino peptidases per gram (LAPU/r, LAPU - Leucine Amino Peptidase Units), "Novozymes, Denmark) to a concentration of 3500 LAPU 50 grams of protein. After about 1 h was started diafiltration by increasing the pressure in retentate to 3 bar inlet pressure of 3 bar. After 5 hours, filtration was stopped and collected retentate. Liofilizirovanny retentate and 7 fractions of permea is a, collected during the process. Subsequently, we determined the content of dry matter (DM) and sialic acid in each fraction. The content of sialic acid was measured after mild acid hydrolysis and tagging using DMB-method (method dihydrochloride 1,2-diamino-4,5-methylenedioxybenzene) and by HPLC analysis on obetovannoi column Shodex 18" with a fluorescence detector using authentic NeuAc as an external standard. Table 1 shows the mass balance and the content of sialic acid in the starting material in the permeate fractions and retentate.

0,02
Table 1
weight (g)NeuAc (% of dry matter)output (%)enrichment
The initial material507,51001,00
permeate 14,320,28,640,03
permeate 23,10,26,2
permeate 36,10,312,20,04
permeate 44,291,48,580,18
permeate 5of 3.560,87,120,10
permeate 62,80,45,60,05
permeate 72,940,35,880,04
retentate22,614.4V45,21,92

The content of galactose and N-atsetilgalaktozamin in retentate was determined after acid hydrolysis using high-performance anion-exchange chromatography on an analytical column Dionex CarboPac PA1" with a pulsed amperometric detector. Briefly, retentate was dissolved in water and added triperoxonane acid to the final concentration is then 2 M The solution was heated for 3 h at 100°C, dried in a stream of nitrogen and pererestorani in the water. After filtration through a 22 μm filter, the sample was analyzed. Quantification was made using authentic galactose and galactosamine (N-atsetilgalaktozamin becomes galactosamine in-process acid), which were used as external controls.

The final dried product from retentate contains 24.4 wt.% (NeuAc)2-Gal-GalNAc-Thr with probable structure NeuAc-α-2,3-Gal-β-l,3-(NeuAc-α-2,6-)-GalNAc-threonine/peptide with molar 43 % sialic acid, 20,5 molar % galactose, 18,4 molar % of N-atsetilgalaktozamin and 18 molar % threonine.

1. Oligosaccharide ingredient that is intended to be added to the nutritional composition or food containing glikozilirovanie amino acids and peptides of the General formula RnSacmwhere R is an amino acid residue, Sac is a monosaccharide selected from the group consisting of N-acetylneuraminic acid, N-atsetilgalaktozamin and galactose, n has a value between 1 and 10 with the proviso that if the value of n is 1, R is a residue of threonine or serine, and if n has a value between 2 and 10, the peptide contains at least one residue is threonine or serine, m has a value from 2 to 4 and N-acetylneuraminic acid is at least 20 mo is.% ingredient, where oligosaccharide ingredient contains from 15 to 25 mol.% N-atsetilgalaktozamin, 15-25 mol.% galactose, 20-50 mol.% N-acetylneuraminic acid and 15 to 25 mol.% threonine or serine, or a mixture thereof.

2. Oligosaccharide ingredient according to claim 1, in which n has a value from 1 to 3.

3. Oligosaccharide ingredient according to claim 1 or 2, in which m has the value 2 or 3.

4. Food product containing oligosaccharide ingredient according to any one of claims 1 to 3.

5. A food product according to claim 4, which is an infant formula.

6. A food product according to claim 5, which contains from 0.2 to 4.0 wt.% oligosaccharide ingredient.

7. The method of obtaining oligosaccharide ingredient according to any one of claims 1 to 3, which includes a step of hydrolysis of casinolocated ectoprocta and endoproteases to obtain a mixture of free amino acids and peptides with a chain length from 2 to 10 and the stage nanofiltration hydrolyzed mixture for selecting the fraction having a molecular weight from 1000 to 2000 Da.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of general formula I [X]n-Y-ZR1R2, wherein the radicals are specified in the description, effective as heparan sulphate-binding protein inhibitors. The invention also refers to a pharmaceutical or veterinary composition having heparan sulphate-binding protein inhibitory activity for preventing or treating a disorder in a mammal, and to the use of these compounds and compositions for antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic therapy in a mammal.

EFFECT: preparing the new compounds of general formula I [X]n-Y-ZR1R2, wherein the radicals are specified in the description, effective as the heparan sulphate binding protein inhibitors.

10 cl, 31 ex, 11 tbl, 40 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a novel compound of structural formula I representing low molecular galactomannan having molecular weight about 702 Daltons and molecular formula C24H46O23. The compound is prepared of parts of the plant Trigonella foenum graecum selected from the group consisting of roots, shoots, leaves, seeds; preferentially seeds. What is also declared is a composition comprising an effective amount of a compound, optionally together with the adjuvants, for improving the body composition, increasing strength and positive effect on the factors associated with pre-diabetic and diabetic conditions.

EFFECT: invention refers to a method for preparing the compound of formula I, as well as to a method of treating pre-diabetic and diabetic diseased conditions in an individual in need thereof.

23 cl, 7 ex, 2 tbl, 8 dwg

FIELD: food industry.

SUBSTANCE: method of oligasaccharide mixture production from animal milk which has the same range of oligasaccharides as milk it was produced from includes the following stages: (a) concentration of deproteines milk material to the total content of dry substance from 50 to 75% given the condition that temperature shall not rise to the level at which hydrolisis or sialic acid reduction take place; (b) concentrated milk is subject to partial lactose removal and preparation of solution with lactose: oligasaccharide ratio less than 250, and (c) demineralization of milk material - at this the stage of demineralization is conducted either before concentration stage or after lactose removal. Also invention refers to the mixture of oligasaccharides recieved this way from animal milk and food products containing the mentioned mixture of oligasaccharides.

EFFECT: receipt of mixture of oligasaccharides.

18 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method of antigen immunogenicity regulation includes incorporation of antigen into structure of immunostimulating complex (TI-complex) - antigen carrier. As protein antigen used is porin from Yersinia pseudotuberculosis, its carrier being immunostimulating complex in form of ultramicroscopic tubules (TI-complex), which consists of mixture of triterpene glycoside cucumarioside A2-2 (CD), cholesterol and polar lipid of monogalactosyldiacylglyceride (MGDG) from marine macrophytes with weight ratio CD:cholesterol:MGMD 6:2:4. Variation of lipid antigen surrounding is achieved due to application of MGDG with various fatty acid composition, separated from various species of marine macrophytes.

EFFECT: method makes it possible to carry out targeted regulation of immune response to antigen not only due to change of quantitative but also qualitative composition of the complex, and obtain new optimal means of specific prevention against causative agents of pseudotuberculosis and other infectious diseases.

3 cl, 6 dwg, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to antithrombotic compound of formula (I) (oligisaccaride-spacer-A(I)), where oligosaccharide is negatively charged pentasaccharide residue of formula given lower, where R5 - OCH3 or OSO3-, charge is compensated by positively charged counterions, and where pentasaccharide residue is obtained from pentasaccharide which has AT-III mediated anti-Xa activity per se; spacer is, in fact, pharmacologically inactive movably bound residue, which has from 10 to 50 atoms long chain; A is residue of -CH[NH-SO2-R1] [CO-NR2-CH(4-benzamidin)-CO-NR3R4], where R1 - 4-methoxy-2,3,6-trimethyphenyl; R2 - H; NR3R4 is piperidinyl group or its pharmaceutically acceptable salt or derivative, where amino group of amidin residue is protected by hydroxyl or (1-6C) alcoxycarbonyl group; where spacer of formula I compound contains one covalent bond with biotin residue of formula -(CH2)4-NR-BT, where R - H or (1-4C)alkyl and BT is residue . Invention also relates to pharmaceutical composition based on formula I compounds for treatment or prevention of thrombosis or other connected with thrombin diseases.

EFFECT: elaboration of antithrombotic compound for treatment or prevention of thrombosis or other, connected with thrombin diseases.

6 cl, 3 tbl, 2 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention refers to sulphated oligosaccharides of the general formula X-[Y]n-Z-UR1, where X, Y and Z each are the same hexose monosaccharide fragment selected out of group including glucose, mannose, altrose, allose, talose, galactose, idose and gulose, adjoining monosaccharide fragments are bound in 1→2, 1→3, 1→4, and/or 1→6 pattern by glycoside bonds, and each carbon atom not binding X, Y and Z groups is bound by single bond with UR group, with exception for carbon atom in 1 position of Z monosaccharide, to which UR1 group is bound by single bond; where n is an integer within 0 to 6; U is O atom or NH; each R is independently C2-C6-alkenyl, benzyl, SO3M or H, where M is any pharmaceutically acceptable cation of alkali metal or organic amine, or R form N3 together with U; R1 is C1-C12alkyl, benzyl, PEG monomethyl ether or its derivative, C1-C12alkylazide, , or , in the form of ester, free acid, free base or hydrate. Also invention refers to pharmaceutical or veterinary composition based on claimed compounds, for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism. Additionally invention refers to application of claimed compounds in medicine production for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism.

EFFECT: increased efficiency of compound application in medicine.

11 cl, 3 tbl, 1 dwg, 16 ex

FIELD: chemistry.

SUBSTANCE: invention pertains to modified polysaccharide in particular to modified polysaccharide Neisseria meningitidis of serogroup A, which preserves immunogenicity, but has improved stability. The modified polysaccharide is obtained from reaction of capsular polysaccharide, or its fragment - oligosaccharide, with CDI type bifunctional reagent, accompanied by reaction with an amino-compound, such as dimethylamine. Description is also given of modified polysaccharide conjugates and vaccines, which are obtained from such conjugates.

EFFECT: obtaining modified saccharide.

70 cl, 17 dwg

FIELD: chemistry.

SUBSTANCE: claimed invention relates to new oligosaccharides modified with fluorophorous marker, namely, 4-O-methylumbelliferyl β-D-xylopiranosil-(1,4)-bis-[O-β-D-xylopiranosil-(1,4)]-β-D-xylopiranoside, 4-O methylumbelliferyl β-D-xylopiranosil-(1,4)-tris-[O-β-D-xylopiranosil-(1,4)]-β-D-xylopiranoside, 4-O-methylumbelliferyl β-D-xylopiranosil-(1,4)-tetrakis-[O-β-D-xylopiranosil-(1,4)]-β-D-xylopiranoside. It is intended for measuring activities of both pure and coarse preparations of β-xylanases. The invention also relates to fermentative synthesis of oligosaccharides with formula: , which lies in incubation of β-xylosidase from Aspergillus sp. at 37°C in neutral reaction medium in presence of aryl-β-D-xylopiranoside and 4-O-methylumbelliferyl-β-D-xylopiranoside.

EFFECT: possibility to measure activities of both pure and coarse preparations of β-xylanases.

4 cl, 1 dwg, 2 tbl

Carrier of antigens // 2322259

FIELD: biotechnology, immunology.

SUBSTANCE: invention proposes a carrier of antigens as a lipid complex consisting of glycoside, cholesterol and lipid. As glycoside a carrier comprises holotoxin A1, and as lipid - monogalactosyldiacyl glycerides (MGDG) of sea macrophytes taken in the weight ratio 3 (holotoxin A1) : 2 (cholesterol) : (2-6) (MGDG). Prepared glycoside-cholesterol-lipid carrier shows stretched threadlike-tubular structure. Use of the prepared carrier of antigens allows enhancing the immunogenic activity of vaccine preparations, and to decrease or remove completely hemolytic toxicity of holotoxin A1, and to eliminate inflammatory, painful, toxic and hemolytic effects of vaccines.

EFFECT: improved and valuable medicinal properties of carrier and vaccines.

4 dwg, 11 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to carriers of antigens. Proposed carrier represents lipid-saponin complex consisting of a mixture of triterpene glycoside, cholesterol and glyceroglycolipid. Cucumarioside A2-2 is used as triterpene glycosides, and monogalacosyldiacylglycerides of sea macrophites are used as glyceroglycolipids. Method involves mixing solutions of cholesterol and glyceroglycolipid in chloroform, evaporation of mixture until dry under vacuum, addition of 3 weight parts of 0.4% aqueous solution of cucumarioside. Then the mixture is solubilized and the total concentration of cholesterol and glyceroglycolipid is brought about to 2 mg in 1 ml of suspension with phosphate-saline buffer at pH 7.2 followed by sonication of the prepared suspension by ultrasonic oscillation device at frequency 20 kHz for 5 min. Method provides preparing the effective adjuvant form of the carrier.

EFFECT: improved preparing method of carrier.

6 cl, 8 dwg, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of general formula I [X]n-Y-ZR1R2, wherein the radicals are specified in the description, effective as heparan sulphate-binding protein inhibitors. The invention also refers to a pharmaceutical or veterinary composition having heparan sulphate-binding protein inhibitory activity for preventing or treating a disorder in a mammal, and to the use of these compounds and compositions for antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic therapy in a mammal.

EFFECT: preparing the new compounds of general formula I [X]n-Y-ZR1R2, wherein the radicals are specified in the description, effective as the heparan sulphate binding protein inhibitors.

10 cl, 31 ex, 11 tbl, 40 dwg

FIELD: chemistry.

SUBSTANCE: use of two carbohydrate residues in the structure of a divalent neoglycoconjugate enables sixfold increase in binding efficiency compared to the monovalent derivative of monolactosyl-L-glutamate-succinate-dihexadecyl-L-glutamic acid, which can be used to produce high-efficiency directed systems for delivering medicinal agents. EFFECT: high affinity of carbohydrate residues to proteins by forming new divalent ligands based on L-glutamic acid diether, which are specific to corresponding receptors which contain residues of different carbohydrates, via a 1,3-dipolar cycloaddition reaction.

2 cl, 2 ex

FIELD: cosmetics, pharmacy.

SUBSTANCE: invention relates to associates containing trehalose and calcium chloride as a crystalline monohydrate comprising above said components and water in the molar ratio = 1:1:1, or as anhydrous crystal containing above said components in the molar ratio = 1:2. Indicated crystals of two species of associates of trehalose and calcium chloride can be used in different branches in production of foodstuffs, cosmetic agents and others.

EFFECT: valuable properties of compounds.

3 cl, 20 tbl, 15 dwg, 30 ex

FIELD: biotechnology, biochemistry, enzymes.

SUBSTANCE: invention relates to a method for preparing 4-O-β-D-galactopyranosyl-D-xylose used for in vivo assay of lactase activity in human intestine. Method involves interaction of D-xylose with β-D-galactopyranoside for 2-48 h in a solution at pH 5-9, at temperature that changes from the mixture freezing point to 45°C, and the following addition of 10-1000 U of β-D-galactosidase per 1 g of β-D-galactopyranoside. Reaction is terminated by inactivation of enzyme followed by isolation and crystallization of fraction containing 4-O-β-D-galactopyranosyl-D-xylose in the crystallization mixture chosen from acetone/methanol = (5-1):(20-1) and acetone/water = (5-1):(20-1). Invention provides increasing content of 4-O-β-D-galactopyranosyl-D-xylose in the final mixture.

EFFECT: improved preparing method.

42 cl, 2 tbl, 9 ex

The invention relates to food industry, namely breast

The invention relates to new derivatives of 3-deoxyanthocyanins formula I, in which X denotes a radical of the formula V or a radical of the formula C; Y denotes a radical of the formula D; R1, R3, R5, R7, R8, R10, R13- the same or different, represent each a linear or branched CNS radical with 1-6 C-atoms or the radical-OSO-3; R2, R4, R6, R9, R11- the same or different, represent each a hydrogen atom, a linear or branched CNS radical with 1-6 C-atoms or the radical-OSO-3, R12means a hydroxyl radical or a radical-OSO-3however , provided that at least one of the substituents R2or R4or R6or R9or R11denotes a hydrogen atom; in the form of pharmaceutically acceptable salts and the corresponding acids

FIELD: food industry.

SUBSTANCE: invention relates to food industry, in particular, to manufacture of biologically active food additives for iodine deficit prophylactics. The biologically active food additive contains potassium iodide - 0.002-0.001 wt %, inuline - 33.33-90.90 wt % and distilled water - balance. The method for production of the biologically active food additive involves an organic compound iodination by way of introduction on inuline into potassium iodide solution, distilled water addition and stirring until creation of a uniform colloidal mass. Stirring is performed at a temperature of 60-70°C during 1-2 hours. Then one proceeds with drying at 25-35°C and the ready product milling.

EFFECT: invention enables extension of the array of agents for iodine deficit prophylactics and to produce a biologically active food additive possessing adjuvant activity with regard to iodine ions.

2 cl, 1 ex

Up!